The prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read moreThe prevalence of Neurological diseases is rising, and available treatments for many of these conditions are either minimally effective or nonexistent. Neurological diseases are one of the primary therapeutic areas where we have chosen to focus our efforts.
Read moreJulius Clinical’s focused approach has created a track record of excellence that testifies to our cardio-metabolic and kidney disease trial capabilities. We have honed our scientific site networks, collaborations with leading experts, and operational resources to deliver steady streams of patients and high-quality data for clients.
Read moreUnrecognised pathogens and reemerging infectious diseases are an ongoing threat to human health in every corner of the world. We contribute to important research in this area by conducting pioneering infectious disease and vaccine trials, doing what we do best: optimizing protocols and executing streamlined trials that deliver high-quality data.
Read more
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR trial outcomes . Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovasc...
Zeist, Netherlands, April 22, 2024 — We proudly welcome Stefan Timmerman as our new Chief Financial Officer (CFO), effective April 1st, following up Eelco Brouwer, who played a crucial role in the completion of the Ampersand transaction last yea...
Zeist, Netherlands, April 5, 2024 — We’re proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strate...
"*" indicates required fields
"*" indicates required fields
